Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | MTOR | P42345 | 1/20 | 0.57 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.57 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.57 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | ST6GAL1 | P15907 | 6/20 | 0.53 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Choline SCHEMBL8755393 | 0.92 | TSHR (0.57) | P2RY2LMNATHRBMTORMDM2 | |
| SCHEMBL15954684 | 0.92 | LMNA (0.57) | P2RY2LMNATHRBMTORMDM2 | |
| SCHEMBL3608348 | 0.92 | LMNA (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| SCHEMBL18151989 | 0.92 | LMNA (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| SCHEMBL29712784 | 0.92 | P2RY2 (0.52) | P2RY2LMNATHRBMTORMDM2 | |
| SCHEMBL2212574 | 0.92 | LMNA (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| SCHEMBL10177274 | 0.92 | LMNA (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| SCHEMBL11617377 | 0.92 | LMNA (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| SCHEMBL4735554 | 0.92 | LMNA (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| SCHEMBL79966 | 0.92 | LMNA (0.69) | P2RY2LMNATHRBMTORMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024239431-A1 | METHOD FOR PHOSPHORYLATION OF NUCLEIC ACID AT 3' END AND LIBRARY CONSTRUCTION | 深圳华大智造科技股份有限公司 | 2024-11-28 | — | — | WO | claimed |
| CN-101705270-A | Method for synthesizing deoxycytidine triphosphate through biotechnology | JIANGSU HUARONG BIOLOG TECHNOL | 2010-05-12 | — | — | CN | claimed |
| US-20250304929-A1 | Enzyme Phosphorylating 2' Hydroxyl Group of RNA | THE UNIVERSITY OF TOKYO (JP) | 2025-10-02 | — | — | US | disclosed |
| WO-2025059367-A1 | TREX-1 AUGMENTATION TO ATTENUATE GENOTOXIC STRESS AND EXERT CARDIOPROTECTION | CEDARS-SINAI MEDICAL CENTER (US) | 2025-03-20 | — | — | WO | disclosed |
| US-20250041324-A1 | CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-02-06 | — | — | US | disclosed |
| WO-2024239431-A1 | METHOD FOR PHOSPHORYLATION OF NUCLEIC ACID AT 3' END AND LIBRARY CONSTRUCTION | 深圳华大智造科技股份有限公司 | 2024-11-28 | — | — | WO | disclosed |
| US-12037579-B2 | Synthetic RNA binding polypeptides | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036231-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2023195544-A1 | ENZYME PHOSPHORYLATING 2'-HYDROXYL GROUP OF RNA | 国立大学法人東京大学 | 2023-10-12 | — | — | WO | disclosed |
| WO-2023154848-A1 | COMPOSITIONS AND METHODS FOR MODULATING NUCLEAR ENRICHED ABUNDANT TRANSCRIPT 1 TO TREAT COGNITIVE IMPAIRMENT | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-4139043-A1 | METHODS FOR DIRECT SEQUENCING OF RNA | New York Institute of Technology (US) | 2023-03-01 | — | — | EP | disclosed |
| WO-1995032283-A1 | SEQUENCE-SPECIFIC ENDONUCLEASES, AND PREPARATION AND USE OF SAME | INDIANA UNIVERSITY FOUNDATION (US) | 1995-11-30 | — | — | WO | disclosed |
| US-5397698-A | Producing multiple copies of primary polynucleotide sequence; cleaving into fragments, dissociation and hybridizing | SYNTEX (U.S.A.) INC. (US) | 1995-03-14 | — | — | US | disclosed |
| EP-0357336-B1 | Method for detection of specific nucleic acid sequences | SYNTEX INC (US) | 1994-10-05 | — | — | EP | disclosed |
| US-5273879-A | Kits containing a single-stranded DNA oligomer bonded at its 3' end to a single-stranded polynucleotide binding sequence complementary to a target sequence; templates; restrictive sites; hybridization | SYNTEX (U.S.A.) INC. (US) | 1993-12-28 | — | — | US | disclosed |
| EP-0300796-B1 | Amplification method for polynucleotide assays | SYNTEX INC (US) | 1993-10-20 | — | — | EP | disclosed |
| US-5185243-A | Hybridizing two nucleotide sequences with a target nucleotide, covalently attaching two nucleotide sequences and determining the presence of covalently attached nucleotide sequences | SYNTEX (U.S.A.) INC. (US) | 1993-02-09 | — | — | US | disclosed |
| US-4994368-A | Forming extension of hybridized polynucleotide sequence, cleaving, dissociating fragments, hybridizing fragments | SYNTEX (U.S.A.) INC. (US) | 1991-02-19 | — | — | US | disclosed |
| EP-0357336-A2 | Method for detection of specific nucleic acid sequences | SYNTEX (U.S.A.) INC. (US) | 1990-03-07 | — | — | EP | disclosed |
| EP-0300796-A2 | Amplification method for polynucleotide assays | SYNTEX (U.S.A.) INC. (US) | 1989-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036231-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | STING1, IRF3, CGAS | P2RY2 229/4885LMNA 4166/4885THRB 2070/4885 |
| US-20250041324-A1 | CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING | STING1, IRF3, CGAS | P2RY2 229/4885LMNA 4166/4885THRB 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.